Can Cannabinoids Help With CDKL5 Deficiency Disorder, a Severe Genetic Epilepsy?
CBD has shown promise for several genetic epilepsies, but specific evidence for CDKL5 Deficiency Disorder remains limited and largely anecdotal.
Quick Facts
What This Study Found
CBD is proven for LGS, Dravet, and TSC. For CDD, evidence relies on anecdotal reports using artisanal products with unknown compositions. Preclinical models could help establish efficacy.
Key Numbers
CDD seizures can exceed 10 daily in severe cases. CBD approved for 3 genetic epilepsies. No clinical trial data for CDD.
How They Did This
Narrative review examining clinical trials and preclinical models of cannabinoids in genetic epilepsies, with focus on CDD.
Why This Research Matters
CDD causes devastating seizures that existing drugs often fail to control. Establishing whether cannabinoids work through CDD-specific pathways could justify targeted trials.
The Bigger Picture
Off-label cannabinoid use is already happening in CDD without adequate evidence. The approved indication list may need to expand.
What This Study Doesn't Tell Us
No CDD trial data. Anecdotal reports use unknown compositions. Molecular overlap with other epilepsies is theoretical.
Questions This Raises
- ?Do cannabinoids interact with CDD-specific molecular pathways?
- ?Should CDD be prioritized for CBD clinical trials?
Trust & Context
- Key Stat:
- CBD approved for 3 genetic epilepsies, but zero trial data for CDKL5 Deficiency Disorder
- Evidence Grade:
- Review relying on extrapolation from other conditions and anecdotal CDD reports.
- Study Age:
- Published in 2024.
- Original Title:
- Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder.
- Published In:
- International journal of molecular sciences, 25(19) (2024)
- Database ID:
- RTHC-05527
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can CBD help CDKL5 Deficiency Disorder?
CBD works for some genetic epilepsies, but CDD evidence is limited to anecdotal reports. Targeted trials are needed.
Why isn't CBD approved for all genetic epilepsies?
Approval requires clinical trial data for each condition. CDD lacks these trials.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05527APA
Massey, Sean; Quigley, Anita; Rochfort, Simone; Christodoulou, John; Van Bergen, Nicole J. (2024). Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder.. International journal of molecular sciences, 25(19). https://doi.org/10.3390/ijms251910768
MLA
Massey, Sean, et al. "Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder.." International journal of molecular sciences, 2024. https://doi.org/10.3390/ijms251910768
RethinkTHC
RethinkTHC Research Database. "Cannabinoids and Genetic Epilepsy Models: A Review with Focu..." RTHC-05527. Retrieved from https://rethinkthc.com/research/massey-2024-cannabinoids-and-genetic-epilepsy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.